| | | Good Afternoon! | Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today. |
|
| | Future of Screen Tech (Sponsored) | | | A tech innovator could enable the mass commercialization of MicroLED displays, securing a partnership with Taiwan’s leading manufacturer. Can this under-the-radar company follow in OLED’s footsteps? Find out more now. |
|
| | Markets 📈 | US stocks bled on Wednesday as investors showed concerns about the impact of tariffs. The market slumped under the pressure from the tech sector. | DJIA [-0.43%] S&P 500 [-1.12%] |
| Nasdaq [-2.04%] Russell 2K [-1.12%] |
|
|
|
| | Market-Moving News 📈 | Grocery | No Eggs in the Basket: Walmart Adapts to Supply Pressures | | Walmart (NYSE: WMT) has updated its 2025 Easter meal promotion by removing eggs from its holiday basket due to persistent supply disruptions caused by a bird flu outbreak. | The retailer’s seasonal offering features a kit with nine core ingredients: ham, potatoes, corn, and dessert. Walmart priced the kit to serve eight people for under $6 per person—below last year’s Easter promotion average. Unlike previous years, however, the kit excludes eggs, a shift the company attributed to existing pantry overlap and ongoing supply volatility. | Egg prices surged over recent months as avian flu continued to affect egg-laying hen populations across the country. In response, some grocery chains introduced purchase limits, and restaurants adjusted their menus. Walmart confirmed that while overall availability remains strained in some regions, it has not imposed broad in-store limits on egg purchases. Online orders for 60-count cartons are currently capped at six units. | The company said its grocery business saw mid-single-digit revenue growth in the most recent quarter, aided partly by higher egg prices. While customers continue to navigate inflation-sensitive categories, Walmart’s decision to keep the Easter offering affordable reflects broader efforts to retain value-focused shoppers. | As the nation’s largest grocer, Walmart’s product selections often barometer supply chain stress and consumer expectations. |
|
| | Next Magnificent 7 (Sponsored) | | | If you missed out on Apple, Tesla, or Amazon in their early days, you know how painful it is to watch those stocks skyrocket without you. | But here’s the good news—history is about to repeat itself. | We’ve identified 7 rapidly growing companies with the potential to become the next big market winners. These firms are innovating, expanding, and still flying under Wall Street’s radar—but not for long. | Get your FREE report: “The Next Magnificent 7 Stocks for 2025” right here. | (By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.) | Just like the original Magnificent Seven—Apple, Microsoft, Amazon, Alphabet, Nvidia, Meta, and Tesla—these companies are positioned for explosive growth. The key is getting in before the crowd. | Opportunities like this don’t last. Once the mainstream catches on, the biggest gains will be gone. | Click here to claim your free report and discover the next market leaders. | (By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.) |
|
| | Beverage | FDA Flags Contamination as Coca-Cola Pulls Soda Packs from Stores | | The Coca-Cola Company (KO) has initiated a voluntary recall of over 10,000 cans of soda distributed across Illinois and Wisconsin. The move follows a notice from the U.S. Food and Drug Administration (FDA), which flagged the presence of plastic material in select 12-can packs of Coca-Cola products. | Federal officials reclassified the recall as a Class II event, indicating that exposure to the affected products may cause temporary or medically reversible health effects. | Retailers and distributors received formal instructions to remove the affected packs from store shelves and halt further distribution. Coca-Cola continues coordinating with regulatory authorities and partners to ensure swift action and maintain consumer trust. | Packaging teams identified the impacted lots through standard quality assurance checks. The company has not provided details regarding the source of contamination but confirmed that no injuries or health incidents have been reported. | This is not the first time the company has responded proactively to safety concerns. Due to isolated quality issues, Coca-Cola issued product recalls in select international markets. | Consumers who purchased the affected products may return them to the point of purchase or contact Coca-Cola’s customer service for support. The company remains engaged with the FDA and local agencies to finalize recall procedures and strengthen its quality controls. |
|
| | | | Healthcare | Abbott Laboratories Secures FDA Nod for Coronary IVL System Trial | | Abbott Laboratories (NYSE: ABT) received approval from the U.S. Food and Drug Administration to begin a clinical trial for its Coronary Intravascular Lithotripsy (IVL) System. This milestone advances Abbott’s efforts to provide less invasive treatment options for patients with coronary artery disease. | The IVL system aims to address hardened calcium deposits within the arteries by using pressure waves to break them down. This allows for better stent placement and improved blood flow. The technology could offer an alternative for patients who face challenges with traditional interventions. | The system will be tested under an Investigational Device Exemption and will assess the device's safety and effectiveness across various patient groups. The trial adds to Abbott’s growing portfolio of cardiovascular innovations, including recent pacemaker developments and diabetes care technologies. | Recent product approvals and strategic collaborations continue solidifying Abbott’s role in advancing medical technology. The company recently expanded efforts in diabetes management and cardiovascular health through new device rollouts and partnerships. | Abbott has also maintained a steady pace of dividend payments and shareholder programs while pursuing long-term growth in key healthcare segments. Its innovation pipeline continues to evolve, focusing on diagnostics, chronic condition management, and minimally invasive treatments. |
|
| | Top Winners and Losers 🔥 | | | Lixiang Education Holding ADR [LXEH] $18.21 (+75.10%) | Lixiang Education, which provides private education services in China, saw its share nearly double today. Recently, the company regained compliance with Nasdaq’s minimum market value of publicly held shares, boosting investor confidence. | Worthington Enterprises Inc [WOR] $51.52 (+23.76%) | Industrial manufacturing company Worthington Enterprises rallied after posting strong quarterly results that beat analysts’ expectations on all fronts, including earnings, sales, and operating income. | Alumis Inc [ALMS] $4.92 (+23%) | San Francisco-based Biotech firm Alumis saw its stock thrive after partnering with Japanese Kaken Pharmaceutical to commercialize its drug in Japan. Alumis may receive a total $180 million in a few years, including $40 million in upfront payments. |
| |
|
| | | | | | Airjoule Technologies Corp [AIRJ] $5.29 (-26.73%) | Airjoule Technologies was in free fall today, touching the lowest level this year. The atmospheric energy and water tech company reported a net loss of $14 million in Q4. On top of that, investors dumped AIRJ after it entered into a $30 million stock purchase agreement, planning to sell shares at a discount. | Nyxoah S A [NYXH] $8.91 (-21.36%) | Nyxoah S.A., a European medical technology company, became one of the worst performers today, even though the US FDA approved its sleep apnea treatment. Investors were disappointed to find out that the launch would be delayed by up to two quarters. | Beta Bionics Inc [BBNX] $13.5 (-13.6%) | Beta Bionics, a US medical device company focusing on diabetes, turned bearish after posting unconvincing annual results and guidance for 2025. |
| |
| | |
| | AI (Sponsored) | | | AI is the new Bitcoin—a transformative opportunity you can’t afford to miss. | Just as Bitcoin turned early believers into millionaires, artificial intelligence is set to define the next era of wealth creation. From revolutionizing industries to reshaping how businesses operate, AI is more than a trend—it’s the future. | We’ve pinpointed 10 AI stocks poised to dominate in 2025. These companies aren’t just riding the wave; they’re leading the charge, harnessing AI to transform sectors like healthcare, finance, and manufacturing. | (By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.) | Don’t be the one looking back and saying, “I wish I had invested early.” This is your chance to get ahead of a movement that could rival the Bitcoin boom. | Click here to uncover the 10 AI stocks primed for explosive growth. | (By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.) |
|
| | That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback! | Thanks for reading. I'll see you at the next open! | Best Regards,
— Adam G.
Elite Trade Club |
|
| | | | Click here to get our daily newsletter straight to your cell for free. | P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. |
| |
|
|
|
